DMAC (DiaMedica Therapeutics) Other Gross PPE: $0.02 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DMAC DiaMedica Therapeutics Inc DMAC
32 GF Score
Price $6.85
! 2 Warning Signs
View Full Analysis

What is DiaMedica Therapeutics Other Gross PPE?

DiaMedica Therapeutics DMAC +4.09% 32 Other Gross PPE is $0.02 Mil as of Jun. 2026. GuruFocus rates DMAC with a GF Score™ of 32/100. The stock has 2 warning signs investors should review.

DiaMedica Therapeutics's Other Gross PPE for the quarter that ended in Jun. 2026 was $0.02 Mil.

DiaMedica Therapeutics's quarterly Other Gross PPE increased from Dec. 2025 ($0.02 Mil) to Mar. 2026 ($0.02 Mil) but then declined from Mar. 2026 ($0.02 Mil) to Jun. 2026 ($0.02 Mil).

DiaMedica Therapeutics's annual Other Gross PPE stayed the same from Dec. 2023 ($0.02 Mil) to Dec. 2024 ($0.02 Mil) but then declined from Dec. 2024 ($0.02 Mil) to Dec. 2025 ($0.02 Mil).

DiaMedica Therapeutics Other Gross PPE Historical Data

* Premium members only.

The historical data trend for DiaMedica Therapeutics's Other Gross PPE can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DiaMedica Therapeutics Other Gross PPE Chart

DiaMedica Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Gross PPE
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.02 0.02 0.02 0.02

DiaMedica Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Gross PPE Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 0.02 0.02 0.02 0.02
DMAC
32GF Score
DiaMedica Therapeutics Inc DMAC
Other Gross PPE is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

DiaMedica Therapeutics Other Gross PPE Calculation

GuruFocus lists Land And Improvements, Buildings And Improvements, Machinery, Furniture, Equipment, Construction In Progress and Other Gross PPE under the "Gross Property, Plant and Equipment" section.

Frequently Asked Questions Learn more about Other Gross PPE →
What does a Other Gross PPE of $0.02 Mil mean?
DiaMedica Therapeutics (DMAC) has a Other Gross PPE of $0.02 Mil as of Jun. 2026. Other Gross PPE is property, plant and equipment recorded on a company's balance sheet that not otherwise classified. View historical data on DiaMedica Therapeutics and its competitors.
Is DiaMedica Therapeutics' Other Gross PPE too high?
DiaMedica Therapeutics' current Other Gross PPE is $0.02 Mil. Overall, DiaMedica Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does DiaMedica Therapeutics' Other Gross PPE compare to XFOR and IKT?
DiaMedica Therapeutics' Other Gross PPE of $0.02 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Gross PPE for a Biotechnology company?
A good Other Gross PPE depends on the Biotechnology industry context. However, Other Gross PPE should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Gross PPE mean?
A high Other Gross PPE can signal that a stock is expensive relative to its fundamentals. Other Gross PPE is property, plant and equipment recorded on a company's balance sheet that not otherwise classified. View historical data on DiaMedica Therapeutics and its competitors. DiaMedica Therapeutics's current Other Gross PPE is $0.02 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DiaMedica Therapeutics stock overvalued right now?
DiaMedica Therapeutics (DMAC) has a current Other Gross PPE of $0.02 Mil. The current Other Gross PPE is $0.02 Mil. DiaMedica Therapeutics' overall GF Score™ is 32/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Gross PPE calculated?
Other Gross PPE is calculated from a company's financial statements. For DiaMedica Therapeutics (DMAC), the current Other Gross PPE is $0.02 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

DiaMedica Therapeutics Business Description

Address 301 Carlson Parkway, Suite 210, Minneapolis, MN, USA, 55305
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
32GF Score

Get the complete analysis for DMAC

Other Gross PPE is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.85
Price